CM Life Sciences, Inc.
Status: Deal Closed
U=S+W/3
W=S@11.5
IPO Proceeds, $M | $442.75M |
---|---|
IPO Date | Sep 2, 2020 |
CEO | Eli D. Casdin |
Left Lead | Jefferies |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 months |
IPO Sector |
Healthcare
Life sciences |
IPO Geography | Global |
Target Company | Sema4 |
Deal Announced | Feb 10, 2021 |
Deal Size, $M | $2,071.00M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Jul 21, 2021 |
Amendment Vote | TBD |
Closing Date | Jul 22, 2021 |
Formerly CMLF
WGS
SMFRW
Price | $79.63 $2.41 |
---|---|
Last closing price | $75.05 |
H/L, today | $74.50 / $80.99 |
Volume, today | 634,627 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on CM Life Sciences, Inc.:
- Structure and cap table
- 8 directors & officers
- 21 filings and events
- 1 underwriters
- 5 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Eli D. Casdin | 47 | CEO and Director |
Keith A. Meister | 47 | Chairman |
Brian Emes | 47 | CFO and Secretary |
Shaun Rodriguez | 42 | CSO |
Munib Islam | 46 | Director |
Sean George | 46 | Director |
Emily Leproust | 47 | Director |
Nat Turner | 34 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Jefferies | BR | 38,500,000 | units |
38,500,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.